RxDoctor Payments Data

Renzo Figari Jordan, MD

Neurology · Charlottesville, VANPI 1588820138

Payments from drug & device makers

$14,067in general payments, 2019–2025

Across 92 payments — averaging $152.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$9K
  • UCB, Inc.$1K
  • Boston Scientific$990
  • Amneal Pharmaceuticals LLC$771
  • AbbVie$451
  • Abbott$150
  • plus $1K from 21 others

What the payments were for

  • Speaking & faculty fees$74115%
  • Travel & lodging$1,86338%
  • Food & beverage$2,17645%
  • Education$872%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,067 in reported general payments places this provider in the 70th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$98,439
Medicare patients
464
Services billed
1,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa52$119,887
NuplazidPimavanserin Tartrate25$116,800
Droxidopa19$24,026
Tetrabenazine11$22,099
Carbidopa-LevodopaCarbidopa/Levodopa419$19,063
Carbidopa-Levodopa ErCarbidopa/Levodopa145$10,076
AmantadineAmantadine Hcl46$2,331
Selegiline Hcl19$2,119
Primidone44$2,113
Ropinirole Hcl29$959
Propranolol Hcl25$944
Gabapentin45$780
Pramipexole DihydrochloridePramipexole Di-Hcl22$704
Quetiapine Fumarate30$701
Atropine Sulfate16$656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$771$119,88752 claims
Acadia Pharmaceuticals IncNuplazid$16$116,80025 claims
Upsher-smith Laboratories LLCTopiramate$12$60841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 474 neurology providers in Virginia.

Other neurology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →